Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 Shares

Prelude Therapeutics Incorporated (NASDAQ:PRLDGet Free Report) CEO Krishna Vaddi bought 47,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were acquired at an average price of $0.71 per share, with a total value of $33,725.00. Following the transaction, the chief executive officer now directly owns 1,214,775 shares of the company’s stock, valued at $862,490.25. This represents a 4.07 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Krishna Vaddi also recently made the following trade(s):

  • On Monday, December 30th, Krishna Vaddi bought 10,000 shares of Prelude Therapeutics stock. The shares were acquired at an average price of $1.20 per share, with a total value of $12,000.00.
  • On Wednesday, December 18th, Krishna Vaddi purchased 100,000 shares of Prelude Therapeutics stock. The shares were purchased at an average price of $0.93 per share, with a total value of $93,000.00.

Prelude Therapeutics Stock Performance

Shares of Prelude Therapeutics stock opened at $0.74 on Friday. The stock has a market cap of $40.99 million, a price-to-earnings ratio of -0.42 and a beta of 1.43. The stock has a 50 day moving average price of $0.97 and a 200-day moving average price of $1.63. Prelude Therapeutics Incorporated has a one year low of $0.66 and a one year high of $6.80.

Prelude Therapeutics (NASDAQ:PRLDGet Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.11. The business had revenue of $4.00 million for the quarter. Sell-side analysts predict that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a “market outperform” rating and set a $4.00 price target (down previously from $7.00) on shares of Prelude Therapeutics in a report on Wednesday, December 11th.

Check Out Our Latest Report on PRLD

Institutional Investors Weigh In On Prelude Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets bought a new stake in shares of Prelude Therapeutics during the 4th quarter worth approximately $26,000. Barclays PLC raised its position in Prelude Therapeutics by 86.0% during the 3rd quarter. Barclays PLC now owns 27,165 shares of the company’s stock valued at $57,000 after purchasing an additional 12,564 shares in the last quarter. XTX Topco Ltd bought a new stake in Prelude Therapeutics during the 3rd quarter valued at $100,000. JPMorgan Chase & Co. raised its position in Prelude Therapeutics by 925.0% during the 4th quarter. JPMorgan Chase & Co. now owns 61,149 shares of the company’s stock valued at $78,000 after purchasing an additional 55,183 shares in the last quarter. Finally, Walleye Capital LLC raised its position in Prelude Therapeutics by 446.2% during the 3rd quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after purchasing an additional 67,946 shares in the last quarter. 79.72% of the stock is owned by institutional investors.

Prelude Therapeutics Company Profile

(Get Free Report)

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.

Recommended Stories

Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.